Subtotal transurethral prostatectomy in the treatment of patients with prostatic cancer


Cite item

Full Text

Abstract

The results are given of subtotal transurethral resection (subtotal TUR) in 21 patients with prostatic cancer (PC) operated in 19982004. The patients had contraindications to radical treatment. The aim of the surgical intervention was maximal possible removal of the prostatic tissue to the prostatic capsule that improves results of adjuvant hormonal and radiotherapy. Postoperative follow-up lasted from 6 months to 6 years. The control groups consisted of 20 patients subjected to palliative prostatic TUR and 24 PC patients given only hormonal or radiotherapy. Subtotal transurethral prostatectomy and TUR of the prostate were successfully made in all the patients. The number of postoperative complications and reoperations was less in patients after subtotal transurethral prostatectomy than in those after palliative TUR. The treatment reduced blood PSA levels in all the groups but the progress of this reduction depended on the treatment method. The group after subtotal transurethral prostatectomy achieved maximal PSA lowering after 2 months after surgery. The follow-up registered distant metastases in 19.04% patients of the study group and 20 and 29.4% in the control groups. One-year survival was 80.95, 80, 83.3%, respectively; 3-year survival was 80, 45.5 and 77.8%, respectively. Thus, combined treatment of prostatic cancer (subtotal transurethral prostatectomy and maximal androgenic blockade) rapidly corrects urination without deterioration of survival parameters compared to hormonal therapy alone.

About the authors

E В Mazo

A K Chepurov

O V Zorya

References

  1. Мартов А. Г., Лопаткин Н. А. Руководство по трансуретральной эндоскопической электрохирургии доброкачественной гиперплазии простаты. М.; 1997.
  2. Доброхотов М. А. Место трансуретральной резекции в диагностике и комплексном лечении рака предстательной железы у больных пожилого и старческого возраста: Дис. ... канд. мед. наук. М.; 2000.
  3. Ассад О. Диагностика и лечение урологических осложнений у больных раком предстательной железы: Дис. ... канд. мед. наук. М.; 2002.
  4. Jonasson О., Long L., Roberts S. et al. Cancer cells in the circulating blood during operative management of genitourinary tumors. J. Urol. (Baltimore) 1961; 85: 1 - 12.
  5. Heung Y. M., Walsh K., Sriprasad S. et al. The detection of prostate cells by the reverse transcription-polymerase chain reaction in the circulation of patients undergoing transurethral resection of the prostate. Br. J. Urol. Int. 2000; 85 (1): 65-69.
  6. Bhatti R., Baumgartner C., Guinan P. et al. Role of transurethral resectioin of the prostate in hematogenously disseminated metastasis. Urol. Int. 1988; 43 (1): 29-31.
  7. Переверзев А. С., Коган М. И. Рак простаты. Харьков; 2004.
  8. Kuban D. A., El-Mahdi A. M. et al. The effect of transurethral resection on the incidence of osseous prostatic metastasis. Cancer (Philad.) 1985; 56 (4): 961-964.
  9. Rodrigues J. V., ChechUe G. Usefulness of transurethral resection in cancer of the prostate. Arch. Esp. Urol. 1989; 42: 165- 177.
  10. Babaian R. J., Archer J. S. Dissemination of disease following transurethral resection for locally advanced prostate cancer. Urology 1988; 31 (1): 30-33.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2005 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies